0001213900-21-001205.txt : 20210108 0001213900-21-001205.hdr.sgml : 20210108 20210108163054 ACCESSION NUMBER: 0001213900-21-001205 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210108 DATE AS OF CHANGE: 20210108 EFFECTIVENESS DATE: 20210108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-385744 FILM NUMBER: 21517800 BUSINESS ADDRESS: STREET 1: 1 ROCKEFELLER PLAZA, SUITE 1039 CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 551-578-2261 MAIL ADDRESS: STREET 1: 1 ROCKEFELLER PLAZA, SUITE 1039 CITY: NEW YORK STATE: NY ZIP: 10020 D 1 primary_doc.xml X0708 D LIVE 0001711786 Hoth Therapeutics, Inc. 1 ROCKEFELLER PLAZA, SUITE 1039 NEW YORK NY NEW YORK 10020 (646) 756-2997 NEVADA None None Corporation true 2017 Robb Knie 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Executive Officer Director Chief Executive Officer and President David Briones 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Executive Officer Chief Financial Officer Stefanie Johns 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Executive Officer Chief Scientific Officer David Sarnoff 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Director Vadim Mats 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Director Graig Springer 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Director Wayne Linsley 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Director Pharmaceuticals Decline to Disclose 06b false 2021-01-07 false true true true false 0 The Benchmark Company, LLC 22982 None None 150 E. 58TH STREET, 17TH FLOOR NEW YORK NY NEW YORK 10155 CA CALIFORNIA IL ILLINOIS NY NEW YORK false 5000000 5000000 0 false 3 350000 true 0 Represents a fee of 7% of the gross proceeds from the sale of securities. Excludes reimbursement of legal expenses in the amount of $50,000 and placement agent warrants to purchase common stock equal to 5% of the securities issued in the offering. 0 false Hoth Therapeutics, Inc. /s/ Robb Knie Robb Knie Chief Executive Officer 2021-01-08